Leveraging our NanoPortal™ technology, we are developing a portfolio of highly differentiated products comprised of miniature, sub-dermal drug implants.
Semaglutide
Semaglutide
Exenatide
Semaglutide
Semaglutide
Exenatide
Semaglutide
Semaglutide
Exenatide
NPM-139, leveraging our NanoPortal™ technology, is designed to provide steady, long-term therapeutic delivery of semaglutide for at least six months.
By assuring medication adherence, NPM-139 may free patients with obesity from burdens associated with oral and injectable medications, as well as provide confidence to physicians, caregivers and loved ones that patients are receiving the intended therapeutic benefits from their medicine.
Although the GLP-1 receptor agonist class has quickly outpaced previous anti-obesity medications due to superior efficacy and tolerability, medication non-adherence continues to affect an alarming number of patients – approximately 50%, including those taking daily pills. In fact, non-adherence may also contribute to the gap in real-world effectiveness compared to the efficacy reported from randomized, controlled, clinical trials.
Our lead program is NPM-139 (semaglutide implant) which is currently under clinical-stage development for chronic weight management. SLIM-1™ is a Phase 1 trial of NPM-139 designed to assess the safety, tolerability, and pharmacokinetics of low-doses of NPM-139 and Wegovy. SLIM-1 demonstrated a strong NPM-139 safety and tolerability profile and an encouraging NPM-139 semaglutide release profile. In addition, there were no rapid drug exposure increases which have been associated with tolerability issues with other GLP-1 therapies. Activities supporting a dose-ranging Phase 2 trial are underway with trial initiation anticipated in 2027.
Built with our NanoPortal™ technology, NPM-133 is designed to provide steady, long-term therapeutic delivery of semaglutide for at least six months.
For patients with type 2 diabetes, the health risks associated with missed doses of prescribed medications can be severe. NPM-133, currently in development, offers the potential for these patients to receive the full therapeutic benefits of semaglutide treatment over six-months or more without interruption, providing convenience and peace-of-mind.